Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
Would a BRAF V600E mutation affect your decision to give adjuvant therapy in a patient with lung cancer?
Related Questions
For NSCLC patients treated with neoadjuvant chemoimmunotherapy and surgery with ypN2 disease, what factors would cause you to recommend PORT?
How would you approach treatment for patients with limited stage small cell lung cancer (SCLC) who, after induction chemotherapy with carboplatin/etoposide, develop a new contralateral lung nodule confirmed as SCLC, while their primary tumor shows a partial response?
Would you offer adjuvant osimertinib in a patient with complete pathologic response to neoadjuvant platinum doublet for a stage IIIA resected EGFR mutant lung adenocarcinoma?
Would you consider starting immunotherapy in a patient with stage IV NSCLC, a high PDL1 level, and active, untreated hepatitis C?
Which patients with metastatic NSCLC with an EGFR mutation would you treat with chemotherapy & osimertinib or amivantamab & lazertinib, and how would you choose between the two regimens?
Would you offer consolidative durvalumab after chemoRT for an isolated mediastinal recurrence of NSCLC that occurred during adjuvant pembrolizumab given for the initial lung cancer?
Has the MARS data for mesothelioma changed whether you would recommend surgery for these patients?
Would you consider using IO alone for lung cancer patients who are PDL1 <1 but have high TMB?
Would you consider the combination of amivantamab and lazertinib in a patient with NSCLC harboring an EGFR exon 19 deletion that transformed to small cell carcinoma on osimertinib, if resistance profiling still detects the EGFR mutation?
What is your approach to radiographically suspicious lung nodules for which initial biopsy was negative for malignancy?